Aclarion, Inc. (NASDAQ:ACON) Short Interest Update

Aclarion, Inc. (NASDAQ:ACON) saw a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 312,500 shares, a growth of 52.7% from the May 31st total of 204,700 shares. Approximately 3.9% of the shares of the stock are sold short. Based on an average daily volume of 2,380,000 shares, the days-to-cover ratio is presently 0.1 days.

Aclarion Price Performance

Shares of Aclarion stock opened at $0.29 on Friday. The business has a 50 day simple moving average of $0.30 and a two-hundred day simple moving average of $1.27. Aclarion has a 12 month low of $0.27 and a 12 month high of $12.48.

Aclarion (NASDAQ:ACON) last announced its earnings results on Wednesday, May 15th. The company reported ($0.44) EPS for the quarter. Aclarion had a negative net margin of 10,246.33% and a negative return on equity of 2,554.98%. The firm had revenue of $0.01 million for the quarter.

Institutional Investors Weigh In On Aclarion

A hedge fund recently bought a new stake in Aclarion stock. Virtu Financial LLC purchased a new stake in Aclarion, Inc. (NASDAQ:ACON) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 115,183 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned about 1.40% of Aclarion as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 7.52% of the company’s stock.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.